WNWenying Niu

Wenying Niu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wenying Niu has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Benjamin Chiang

    Jewish Hospital Cardiothoracic Surgical Research Institute, Department of Surgery, University of Louisville, Louisville, KY, USA

    1 shared publication
  • Fengjin Li

    The Heilongjiang University of Chinese Medicine, Harbin 150040, China

    1 shared publication
  • Futing Zhang

    Centre Algatech, Institute of Microbiology of the Czech Academy of Sciences, Trebon, Czechia

    1 shared publication
  • Genli Liu

    The Heilongjiang University of Chinese Medicine, Harbin 150040, China

    1 shared publication
  • Hongbin Xiao

    School of Basic Medical Sciences Heilongjiang University of Chinese Medicine Harbin China

    1 shared publication
  • Hongbin Xiao

    College of Basic Medicine, Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang, China

    1 shared publication

Latest Publications

  • Open Access

    Buyang Huanwu Decoction Alleviates Bleomycin‐Induced Pulmonary Fibrosis via Wnt/β‐catenin and TGF‐β1/Smad Pathways

    by Yunyue Zhou, Xingtong Chen, Jinbiao Yang, Shuang Xue, Qiao Wang, Hongbin Xiao, Yukun Zhang, Wenying Niu

    Pulmonary fibrosis (PF) is a chronic, progressive interstitial lung disease. Buyang Huanwu Decoction (BHD) contains PF‐improving compounds; it was separated into supernatant (SN) and precipitation component (PC) via water extraction and ethanol precipitation method to explore their differential PF effects, mechanisms, and screen the most effective fraction. Ultra‐high‐performance liquid chromatography‐mass spectrometry and network pharmacology identified BHD compounds and predicted PF targets. Twelve rats (Control, BHD, PC, and SN groups) were used to detect amygdalin, formononetin, kaempferol, ferulic acid, and paeoniflorin in drug‐containing serum. A rat PF model was established via intratracheal bleomycin (BLM) instillation. Seventy‐two rats were divided into six groups: Control, BLM, BHD, prednisone acetate, SN, and PC. After 21‐day treatment, Hematoxylin and Eosin/Masson staining, alkaline hydrolysis (Hydroxyproline), enzyme‐linked immunosorbent assay (tumor necrosis factor‐α/interleukin‐6), immunofluorescence (alpha‐smooth muscle actin), reverse transcription‐quantitative polymerase chain reaction, and Western Blotting (Wnt/β‐catenin and TGF‐β1/Smad pathways) were used. The SN group exhibited higher serum levels of amygdalin, formononetin, and ferulic acid than the BHD and PC groups, with kaempferol similar to the BHD group. BHD, PC, and SN alleviated BLM‐induced lung inflammation and collagen deposition, reduced Wnt3a, glycogen synthase kinase 3 beta, β‐catenin, and transforming growth factor beta 1 (TGF‐β1) mRNA/protein expression, and decreased the p‐Smad3/Smad3 ratio. BHD and its fractions alleviate PF through dual inhibition of Wnt/β‐catenin and TGF‐β1/Smad pathways, with SN demonstrating the highest overall efficacy.

  • Open Access

    Effects of Different Components of Buyang Huanwu Tang on the PPAR γ /LXR α /ABCA1 Pathway in Hypercholesterolemia Mouse Model

    by Shuaihu Yang, Yukun Zhang, Xinxin Liu, Xingtong Chen, Yuxue Ma, Shijian Fang, Ruihong Yang, Jinbiao Yang, Yunyue Zhou, Xiao He, et al.

    The aim of this study is to compare the effects of different components of Buyang Huanwu Tang (BYHWT) on the peroxisome proliferator‐activated receptor γ (PPAR γ )/liver X receptor α (LXR α )/ATP‐binding cassette transporter A1 (ABCA1) pathway and its lipid‐lowering effects. This study shows that the BYHWT alcohol precipitation and 75% alcohol components can significantly reduce the serum levels of triglycerides (TGs), low‐density lipoprotein (LDL), cholesterol (CHO), and hepatic function damage indicators such as glutamic oxaloacetic transaminase (AST) and glutamic pyruvic transaminase (ALT) in hypercholesterolemia mouse model. After treatment, the presence of lipid droplets in liver cells was reduced, and the destruction of adipocytes was improved. The Western blot (WB) results showed that alcohol precipitation and 75% alcohol components can upregulate PPAR γ , ABCA1, and LXR α . The expression of these components indicates that PPAR γ upregulation can activate LXR α , thus regulating the expression of ABCA1, mediating CHO efflux, promoting reverse cholesterol transport (RCT), and regulating the downstream gene CYP7A1 to participate in bile acid synthesis and metabolism. In summary, the experimental results indicate that the BYHWT alcohol precipitation, 50% alcohol, and 75% alcohol components can modulate the PPAR γ /LXR α /ABCA1 pathway in hypercholesterolemia mouse model to promote CHO metabolism.

  • Open Access

    YiQi YangYin Decoction Attenuates Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Rats

    by Fengjin Li, Genli Liu, Piliang Xue, Zhen Ren, Peifang Dai, Wenying Niu, Mu Xin

    Background. YiQi YangYin Decoction (YQ) is a modern Chinese formula composed by the guidance of traditional Chinese medicine theory, which consists of nine traditional Chinese medicines and is applied to treat type 2 diabetes mellitus (T2DM) with nonalcoholic fatty liver in clinic in China for more than a decade. This study aims to evaluate the antidiabetes and lipid-lowering effect of YQ and explore the possible mechanisms of this action. Methods. T2DM rat models were established and given YQ at three different doses for three weeks. Tissues, including pancreas islet and liver, and blood serum were collected. The levels of fasting blood glucose (FBG), fasting insulin (Fins), lipid index, such as total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL), and hepatic function index such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) in serum were measured. Pancreas islet damage and liver damage were observed by hematoxylin and eosin staining. The glycogen content and lipid accumulation in liver were determined by periodic acid-Schiff (PAS) staining and Oil Red O staining. The expression levels of insulin receptor substrate 2 (IRS-2), phosphatidylinositol 3 kinase-associated p85alpha (PI3K p85α), AKT, and Glucose Transporter 2 (Glut4) in pancreas islet and AMP-activated protein kinase alpha (AMPKα), sterol regulatory element-binding protein 1c (SREBP1c), acetyl-CoA carboxylase (ACC1), and peroxisome proliferatoractivated receptor-α (PPARα) in liver were determined by western blotting. The relative expressions of ACC1, fatty acid synthase (FAS), stearoyl-CoA desaturase 1 (SCD1), carnitine palmityl transferase-1 (CPT-1), and SREBP-1 mRNA were detected by qRT-PCR. Results. After administering YiQi for three weeks, the levels of fast blood glucose, fasting insulin, TC, TG, LDL, ALT, AST, and ALP were significantly decreased, while HDL significantly increased compared with the model group. YQ could obviously attenuate pancreatic damage and improve islet α- and ß-cell survival compared with the model group. Furthermore, YQ could attenuate hepatic damage caused by lipid accumulation, decrease the content of lipid, and increase the hepatic glycogen content, compared with the model group. In addition, YQ remarkably elevated the proteins expression of p-PI3K, p-AKT, and GLUT4 in pancreas islet and elevated the proteins expression of p-PI3K, p-AKT, GLUT4, p-AMPK, SREBP1, and PPARα and inhibited the expression of p-ACC1 in liver. Besides, YQ reduced the relative expression of ACC1, FAS, SERBP-1c, and SCD mRNA along with the decreased production of CPT-1 mRNA. Conclusions. YQ could attenuate type 2 diabetes mellitus by improving islet α- and ß-cells via IRS-2/AKT/GLUT4 pathway and nonalcoholic fatty liver by ameliorating lipid accumulation via AMPK/PPARα/SREBP1/ACC1 pathway.


  • Fructose-1,6-diphosphate and a glucose-free solution enhances functional recovery in hypothermic heart preservation

    by Sufan Chien, Futing Zhang, Wenying Niu, William Ehringer, Benjamin Chiang, Xuejun Shi, Laman A Gray Jr